BeOne Medicines (ONC) Tax Provisions (2015 - 2026)

BeOne Medicines (ONC) has reported Tax Provisions for 12 consecutive years, with $75.5 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Tax Provisions rose 1342.95% year-over-year to $75.5 million in Q2 2026; TTM through Jun 2026 was $212.4 million, a 85.58% increase from a year earlier, with the FY2025 full-year figure at $129.9 million, up 16.22% from the prior year.
• Tax Provisions was $75.5 million for Q2 2026 at BeOne Medicines, up from $31.9 million in the prior quarter.
• Over five years, Tax Provisions peaked at $82.7 million in Q4 2025 and troughed at $5.2 million in Q2 2025.
• A 5-year average of $24.9 million and a median of $14.4 million in 2022 frame the typical range for Tax Provisions.
• Across the five-year window, Tax Provisions soared 3639.57% in 2022 and sank 63.9% in 2025, its largest moves.
• Over 5 years, Tax Provisions stood at $14.4 million in 2022, then climbed by 16.78% to $16.8 million in 2023, then soared by 296.46% to $66.5 million in 2024, then climbed by 24.36% to $82.7 million in 2025, then decreased by 8.81% to $75.5 million in 2026.
• The last three Tax Provisions figures came in at $75.5 million (Q2 2026), $31.9 million (Q1 2026), and $82.7 million (Q4 2025), per Business Quant data.